Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) pose major public health concerns worldwide. HCV is clearly associated with the occurrence of hepatocellular carcinoma, and recently HIV infection has also been linked to the development of a multitude of cancers. Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-b-
A number of viruses including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human papillomavirus (HPV), human T-cell leukemia virus type 1 (HTLV-1), human herpesvirus-8 (HHV-8) and Epstein-Barr virus (EBV) have been associated with different types of cancer. For instance, HIV infection is strongly implicated in the incidence of Kaposi's sarcoma, B-cell non-Hodgkin's lymphoma and invasive cervical cancer (Berretta et al., 2003) . Similarly, it is known that HCV infection is strongly associated with the development of liver cancer and is the primary cause for half of the cases of hepatocellular carcinoma (Liang and Heller, 2004; Radhakrishnan et al., 2004; Levrero, 2006 ). An attractive strategy against these virus-mediated cancers is targeting the virus itself. Both preventive as well as curative methods can be successfully employed to target the virus. One example of a preventive method is the recently licensed vaccine against HPV (Roden and Wu, 2006) , a virus which is strongly associated with the development of cervical cancer. However, in cases where the viral infection and hence the resultant cancer is well established, a curative approach may be more appropriate. In these special situations, an antiviral agent also acts indirectly as an anticancer agent. Given the paucity of current approaches against HIV-and HCV-induced tumorigenesis, in this study we tested our recently characterized anticancer agent ARC (4-amino-6-hydrazino-7-b-Dribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) against HIV-1 and HCV and found that ARC can antagonize both of these viruses.
It is estimated that more than 40 million people worldwide are infected with HIV (www.who.int/hiv/ epiupdates). Although there is no cure for HIV infection, the quality of life of the patients can be dramatically improved by the highly active antiretroviral therapy (HAART). Currently available HIV-1 inhibitors target two of the viral proteins-protease and reverse transcriptase. As drug resistance is a major problem in therapy, it is essential to identify more targets, both viral and cellular, in order to combat HIV infection. Another virus that demands attention due to the sheer number of infected patients worldwide (B170 million) is HCV. The currently favored therapy against HCV is polyethylene glycol (PEG)-interferon-a in combination with ribavirin, which only has a modest success rate. Hence, there is an urgent need for the development of new agents against HCV.
Positive transcription elongation factor b (P-TEFb; a complex of cell cycle-dependent kinase 9 (CDK9)/cyclin T1), apart from its involvement in cellular transcription, also plays an important role in the life cycle of a number of viruses including HIV, human T-lymphotropic virus (HTLV), EBV and human cytomegalovirus (HCMV) (Garber et al., 1998a; Tamrakar et al., 2005; Bark-Jones et al., 2006; Zhou et al., 2006) . The dependence of HIV transcriptional activator (Tat) on P-TEFb has been especially well studied (Brady and Kashanchi, 2005) . The activation domain of Tat (amino acids 1-48) interacts with cyclin T1, whereas the positively charged RNA-binding domain of Tat (amino acids 49-57) binds to TAR RNA (Marcello et al., 2001; Liang and Wainberg, 2002; Brigati et al., 2003; Giacca, 2004) . The interaction of HIV-1 Tat with the bulge of TAR RNA and with cyclin T1 promotes binding of cyclin T1 to the apical loop sequences of TAR RNA (Garber et al., 1998a, b) . Consequently, CDK9/cyclin T1 is recruited to the HIV-1 promoter (Bieniasz et al., 1998; Wei et al., 1998) . Development of drugs that specifically inhibit CDK9 would therefore be of a great benefit for the anti-HIV-1 therapeutics. Previously, flavopiridol, a CDK inhibitor, was shown to be a specific inhibitor of CDK9 in vitro and a potent inhibitor of HIV-1 transcription in cultured cells (Chao et al., 2000) .
In a previous study, we had demonstrated that ARC is a robust inhibitor of P-TEFb in vitro . Here, in order to test if ARC could inhibit HIV-1 Tat-activated transcription, we infected HeLa-CD4-LTR-b-gal cells (MAGI) containing integrated HIV-1 LTR-LacZ with adenovirus expressing Tat (Ad-Tat) (Ammosova et al., 2003) . In MAGI cells, HIV-1 transcription was detectable after the infection with Ad-Tat ( Figure 1a ) but not with a non-relevant adenovirus expressing enhanced green fluorescent protein (EGFP) (not shown). Tat-transactivation was dose dependent and reached maximum at 100-1000 PFU per cell with about 30-fold increase in transactivation of HIV-1 LTR at 24 h post-infection ( Figure 1a) . The b-galactosidase activity was determined using o-nitrophenyl-b-D-galactopyranoside. We then expressed dominant-negative CDK9 using previously described adenoviral vector (Ad-dnCDK9, Sano et al., 2002) that was able to antagonize Tat-based transactivation in MAGI cells (Figure 1b ). This effect was relatively more pronounced than the growth inhibition on these cells imparted by CDK9 inhibition ( Figure 1b ). Next, in order to see if ARC could recapitulate the effects of dnCDK9, we infected MAGI cells with Ad-Tat, and subsequently treated with ARC (1 nM-10 mM) for 24 h. The treatment with ARC potently inhibited Tattransactivation with IC 50 ¼ 0.15 mM (Figure 1c ). Treatment with ARC also reduced cell proliferation, although it required fivefold higher concentrations (IC 50 ¼ 0.8 mM) for the 50% inhibition of cell growth ( Figure 1c ).
We then examined the effect of ARC on HIV-1 transcription in CEM cells containing an integrated HIV-1-GFP (CEM-GFP). HIV-1 transcription was induced with Ad-Tat. Tat A novel anticancer agent S Nekhai et al that was previously shown to downregulate HIV-1 transcription in these cells (Wang et al., 2001) , exhibited an IC 50 of 4.4 mM (data not shown), which is an order of magnitude higher than ARC. Treatment with ARC also affected the viability of CEM-GFP cells albeit at relatively higher concentrations (Figure 2b , IC 50 ¼ 1.3 mM). The difference in IC 50's for cell viability versus transactivation was B4-fold which is consistent with the difference observed in the MAGI system ( Figure 1c) . Next, we wanted to determine whether the inhibition of Tat-dependent transcription by ARC was not due to the reduced expression of Tat. HIV-1 transcription was activated by addition of purified Tat protein to the culture medium (Ammosova et al., 2003) . The purified Tat increased HIV-1 transcription about fivefold but the effect was specific as inactive mutant Tat C22G (Herrmann and Rice, 1995) did not induce EGFP expression (Figure 2c ). Treatment with 1 mM ARC inhibited HIV-1 transcription induced by the extracellular Tat (Figure 2c ). Thus, inhibition of HIV-1 transcription by ARC was not the result of a decreased expression of Tat. Taken together, our data indicate that ARC potently inhibits Tat-based transactivation and HIV-1 transcription in these in vitro model systems. Next, to test if ARC can inhibit HCV replication, we used human hepatoma cell lines (Huh-7) harboring either a subgenomic (Clone B) or a full-length (FLN/ CON) RNA replicon of HCV (Blight et al., 2000 (Blight et al., , 2002 . We found in preliminary experiments that 5-100 mM of ARC was non-toxic to these cells (data not shown). We then treated these cell lines with 5 and 20 mM of ARC and performed real-time reverse transcription-polymerase chain reaction (RT-PCR). We found that ARC was able to potently repress both the subgenomic and full-length replicons at these concentrations (Figure 3a) . To test if the effects of ARC on these replicons can be explained by transcriptional repression alone, we used Actinomycin D, which is a well-established transcriptional inhibitor that works by intercalating within the DNA (Sobell, 1985) . We found that at a concentration (5 mg/ml) in which Actinomycin D is capable of repressing transcription (as seen by decline in mRNA levels of p21, hdm2 and survivin; data not shown), it had no effect on replicon levels in FLN/CON cells, whereas ARC reproducibly repressed the replicon (Figure 3b ). This is consistent with an earlier study where it was shown that HCV RNA replication is resistant to Actinomycin D (Lohmann et al., 1999) . This suggests that ARC may possess additional properties other than transcriptional repression that may contribute to the inhibition of HCV replicon. To evaluate the possibility that ARC inhibits protein translation, we determined the effect of ARC on protein synthesis in reticulocyte cell-free system (Petryshyn et al., 1984) . The treatment of reticulocyte lysate with ARC resulted in the inhibition of protein translation as determined by incorporation of ( 35 S) methionine (Figure 3c ). ARC inhibited protein translation with IC 50 ¼ 50710 mM (Figure 3c ). We also compared ARC with poly(I-C), that inhibits protein translation by activating PKR and inducing the phosphorylation of eukaryotic initiation factor 2 a (Nekhai et al., 2000) . We observed similar inhibition of protein translation with 100 mM ARC and with (Ammosova et al., 2005) were expressed in Escherichia coli and purified on an Aquapore RP-300 column (Applied Biosystems, Foster City, CA, USA) by reversed-phase chromatography as we described previously (Deng et al., 2002) . CEM-GFP cells were treated in a 96-well plate with purified recombinant Tat added at 0.8 mg per 300 000 cells per well along with 100 mM chloroquine (Ammosova et al., 2003) , and with the indicated concentrations of ARC. Cell cultures were continued for 24 h. GFP fluorescence was measured on luminescence spectrometer. Data presented in arbitrary fluorescence units. 50 ng/ml poly(I-C) (Figure 3d ). These experiments rule out translational repression as a mode of action of ARC. At present, we do not know the exact molecular mechanism behind the repression of HCV replication by ARC. It is possible that ARC being a nucleoside analog is misincorporated into the viral RNA by the RNAdependent RNA polymerase (RdRp) of HCV, similar to the mode of action of ribavirin (Lau et al., 2002) . Another possibility is that HCV replication requires CDK9 function at some stage, and ARC's ability to inhibit this kinase may be the reason behind the repression. Further studies are underway to test each of these hypotheses, which will not only clarify the mechanism of action of ARC, but also hopefully contribute towards understanding HCV replication.
In summary, our data establish ARC as a potential agent against HIV-1 and HCV. It remains to be tested if other viruses that depend on P-TEFb are susceptible to ARC. Nevertheless, ARC appears to be a promising candidate for the development of antiviral therapeutics against HIV-1 and HCV, and therefore could be useful against cancers induced by these viruses. (Blight et al., 2000 (Blight et al., , 2002 were grown in DMEM containing 10% FBS (Invitrogen), 1% antibiotic solution and 500 mg/ml G418 (Invitrogen). These Clone B and FLN/CON cells were treated with ARC as indicated for 24 h after which real-time quantitative PCR was performed as described . RNA was extracted by the TRIzol method (Invitrogen). cDNA was synthesized using the SuperScript First Strand Synthesis Kit according to the manufacturer's recommendations (Invitrogen). HCV-specific primers (sense, 5 0 -GTC TAG CCA TGG CGT TAG TA-3 0 ; antisense, 5 0 -CTC CCG GGG CAC TCG CAA GC-3 0 ) were used to measure the levels of replicon. Cyclophilin (sense, 5 0 -GCA GAC AAG GTC CCA AAG ACA G-3 0 ; antisense, 5 0 -CAC CCT GAC ACA TAA ACC CTG G-3 0 ) levels were used for normalization of the data. Quantitative PCRs were run using the ABI 7900 HT system. The purity of the amplified products was ascertained by generating dissociation curves. Quantitation was carried out using a standard curve generated from the simultaneous amplification of the serial dilutions of the cDNA from untreated control cells. Mid points of the log phase of the amplification curves as determined by the PCR machine were used for quantitation. (b) FLN/CON cells were treated with ARC and Actinomycin D as indicated and the levels of HCV replicon were determined by real time quantitative PCR as described above. The levels of 18S rRNA (sense, 5 0 -GTC TGT GAT GCC CTT AGA TG-3 0 ; antisense, 5 0 -AGC TTA TGA CCC GCA CTT AC-3 0 ) were used as normalization control. (c) To measure the rate of translation in vitro, rabbit reticulocyte lysate (100 ml, Ambion, Austin, TX, USA) was supplemented with 7.5 ml Â 20 translation mix (-methionine) (Ambion), 100 mCi radioactive ( 35 S) methionine (Amersham, Piscataway, NJ, USA) and with hemin (20 mM). A typical 25 ml translation reaction contained 19 ml of reticulocyte lysate mix and the indicated concentration of ARC or 150 ng/ml poly(I)-poly(C). The translation reactions were incubated at 301C and 3 ml aliquots were taken at different time points to analyse the kinetics. The 3 ml aliquot was mixed with 0.5 ml of decolorizing solution (1 N NaOH, 1 mM L-methionine and 1.5% H 2 O 2 ) and incubated for 10 min at room temperature to decolorize. Then 1 ml of 25% trichloroacetic acid (TCA) was added and incubated for 5 min on ice. The TCA precipitated proteins were collected by filtration on glass GFC filter (Whatman). The filter was washed twice with 10% TCA, twice with 95% ethanol, air dried and counted in the liquid scintillation counter. Based on the kinetics measurement, the 20 min incubation time was chosen for the ARC experiment. (d) ARC (100 mM) was compared with 150 ng/ml poly(I)-(C) for the level of the inhibition of translation in the rabbit reticulocyte system (described above).
